Elisa Fontana, Jeff Meyers, Alberto Sobrero, Timothy Iveson, Anthony F Shields, Julien Taieb, Takayuki Yoshino, Ioannis Souglakos, Elizabeth C Smyth, Florian Lordick, Markus Moehler, Anne Giraut, Andrea Harkin, Roberto Labianca, Jeffrey Meyerhardt, Thierry André, Ioannis Boukovinas, Sara Lonardi, Mark Saunders, Dewi Vernerey, Eiji Oki, Vassilis Georgoulias, Irit Ben-Aharon, Qian Shi
PURPOSE: Early-onset (EO) colorectal cancer (CRC, age < 50 years) incidence is increasing. Decisions on optimal adjuvant therapy should consider treatment adherence, adverse events, and expected outcomes in a population with life expectancy longer than later-onset (LO) CRC (age ≥ 50 years). MATERIALS AND METHODS: Individual patient data from six trials in the International Duration Evaluation of Adjuvant Chemotherapy database were analyzed. Characteristics, treatment adherence, and adverse events in stage II or III EO-CRC and LO-CRC were compared...
December 20, 2021: Journal of Clinical Oncology